Pembrolizumab, exemestane, and leuprolide in premenopausal estrogen receptor-positive/HER2-negative advanced breast cancer
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/SRP494710
下载链接
链接失效反馈官方服务：
资源简介：
We evaluated the efficacy of combining pembrolizumab (anti-PD1 antibody), exemestane (nonsteroidal aromatase inhibitor), and leuprolide (gonadotropin-releasing hormone agonist) for 15 patients with ER+/HER2- premenopausal MBC who had failed one to two lines of hormone therapy without chemotherapy. Overall design: We performed transcriptome analysis on pre-treatment samples.
创建时间：
2025-01-28
